Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass azithromycin administration safety and antimicrobial resistance study in infants in Nigeria
PACTR202408807120356Phase 4Recruiting
- Sponsor
- Gates Foundation
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of azithromycin in childhood mortality (U5MR) and bacterial colonization, sponsored by Gates Foundation. Primary endpoints: Incidence of serious adverse events and adverse events and Phenotypic macrolide resistance in respiratory and enteric bacteria. Started May 2021; status: recruiting.
02
Drugs
azithromycin
03
Conditions
childhood mortality (U5MR)bacterial colonization
Beyond the preview
Go deeper on PACTR202408807120356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202408807120356.